Protagonist Therapeutics, Inc. (PTGX) Ownership
PTGX ownership summary
as of October 17, 2026- Institutions
- 119.7% of shares outstanding
- Insiders
- 0.71% of shares outstanding
- Shares outstanding
- 64.7M
- Float
- 52.9M shares available to trade
- Short interest
- 16.78% 9.3M shares short
- Days to cover
- 13.63 short interest up 14.8% vs prior month
- Institutions 119.69%
- Insiders 0.71%
PTGX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 15.93% | 10.3M | $1.33B | +528,468 (+5.4%) | June 30, 2026 |
| 2 | Farallon Capital Management, L.L.C. | 9.81% | 6.3M | $817.4M | — | June 30, 2026 |
| 3 | RTW INVESTMENTS, LLC | 7.82% | 5.1M | $651.6M | +2,122 (+0.0%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 5.61% | 3.6M | $467.3M | +148,087 (+4.3%) | June 30, 2026 |
| 5 | Wellington Management Company LLP | 5.28% | 3.4M | $439.9M | −182,863 (−5.1%) | June 30, 2026 |
| 6 | UBS Group AG | 5.25% | 3.4M | $437.6M | −1.8M (−34.4%) | June 30, 2026 |
| 7 | State Street Corp | 5.13% | 3.3M | $427.7M | +204,805 (+6.6%) | June 30, 2026 |
| 8 | HHG PLC | 4.47% | 2.9M | $372.3M | +241,546 (+9.1%) | March 31, 2026 |
| 9 | Vanguard Capital Management, LLC | 4.41% | 2.9M | $367.4M | +47,498 (+1.7%) | June 30, 2026 |
| 10 | Johnson & Johnson | 3.79% | 2.4M | $315.3M | — | June 30, 2026 |
| 11 | Amvescap Plc. | 3.62% | 2.3M | $301.4M | +175,997 (+8.1%) | June 30, 2026 |
| 12 | T. Rowe Price Associates, Inc. | 3.32% | 2.1M | $276.8M | +484,165 (+29.1%) | June 30, 2026 |
| 13 | Jupiter Topco LLC | 3.29% | 2.1M | $274.2M | +2.1M (0.0%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.69% | 1.7M | $224.2M | +71,838 (+4.3%) | June 30, 2026 |
| 15 | Woodline Partners LP | 2.19% | 1.4M | $182.1M | — | June 30, 2026 |
| 16 | Bank of America Corp | 2.05% | 1.3M | $170.5M | +29,064 (+2.2%) | June 30, 2026 |
| 17 | Jennison Associates LLC | 1.78% | 1.2M | $148.3M | +79,670 (+7.4%) | June 30, 2026 |
| 18 | Perceptive Advisors LLC | 1.52% | 982K | $126.4M | −249,000 (−20.2%) | June 30, 2026 |
| 19 | ADAR1 Capital Management LLC | 1.48% | 961K | $123.7M | −33,256 (−3.3%) | June 30, 2026 |
| 20 | Morgan Stanley - Brokerage Accounts | 1.40% | 906K | $116.6M | −112,230 (−11.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 4.1M shares and 5 cut 2.4M.
PTGX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 5.96% | 3.9M | $496.3M | +804 (+0.0%) | September 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 3.17% | 2.0M | $263.9M | −2,836 (−0.1%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.46% | 1.6M | $205.3M | −14,916 (−0.9%) | September 30, 2026 |
| 4 | Vanguard Small Cap Index | 2.29% | 1.5M | $190.5M | +1,138 (+0.1%) | August 31, 2026 |
| 5 | Vanguard Health Care Inv | 2.13% | 1.4M | $177.7M | −177,650 (−11.4%) | June 30, 2026 |
| 6 | State Street® SPDR® S&P® Biotech ETF | 1.58% | 1.0M | $131.3M | −19,400 (−1.9%) | September 30, 2026 |
| 7 | Vanguard MStar Small Cap Growth Indx Inv | 1.31% | 849K | $109.3M | −6,642 (−0.8%) | August 31, 2026 |
| 8 | Invesco Discovery A | 1.25% | 806K | $103.8M | −42,722 (−5.0%) | August 31, 2026 |
| 9 | Fidelity Small Cap Index | 1.04% | 673K | $86.6M | +5,659 (+0.8%) | July 31, 2026 |
| 10 | Fidelity Select Biotechnology | 0.94% | 608K | $78.2M | — | August 31, 2026 |
| 11 | iShares S&P Small-Cap 600 Growth ETF | 0.93% | 599K | $77.2M | — | September 30, 2026 |
| 12 | State Street SPDR Port S&P 600 Sm CpETF | 0.91% | 589K | $75.9M | — | September 30, 2026 |
| 13 | iShares Russell 2000 Growth ETF | 0.89% | 576K | $74.2M | −730 (−0.1%) | September 30, 2026 |
| 14 | Invesco S&P SmallCap Momentum ETF | 0.85% | 551K | $71.0M | — | September 30, 2026 |
| 15 | T. Rowe Price Health Sciences | 0.82% | 534K | $68.7M | −243,500 (−31.3%) | August 31, 2026 |
| 16 | Vanguard Explorer Inv | 0.81% | 524K | $67.4M | +191,210 (+57.5%) | June 30, 2026 |
| 17 | Janus Henderson Triton D | 0.80% | 517K | $66.6M | — | August 31, 2026 |
| 18 | iShares Biotechnology ETF | 0.74% | 477K | $61.5M | −3,616 (−0.8%) | September 30, 2026 |
| 19 | American Century Small Cap Growth Inv | 0.70% | 456K | $58.7M | +48,999 (+12.0%) | June 30, 2026 |
| 20 | Hood River Small-Cap Growth Instl | 0.68% | 438K | $56.3M | −7,730 (−1.7%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
PTGX insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-20 | Asif Ali | Sell | $105.47 | 1,750 | $184,572 |
| 2026-03-26 | Arturo Md Molina | Sell | $104.79 | 15,000 | $1.6M |
| 2026-03-26 | Asif Ali | Sell | $104.24 | 24,765 | $2.6M |
| 2026-03-26 | Harold E Selick | Sell | $105.00 | 24,000 | $2.5M |
| 2026-03-25 | Dinesh V Ph D Patel | Sell | $101.00 | 54,641 | $5.5M |
| 2026-03-24 | Dinesh V Ph D Patel | Sell | $101.00 | 59 | $5,959 |
| 2026-02-17 | Lewis T Williams | Sell | $82.42 | 18,000 | $1.5M |
| 2026-02-06 | William D Waddill | Sell | $83.68 | 20,000 | $1.7M |
| 2026-01-27 | Arturo Md Molina | Sell | $82.00 | 5,000 | $410,000 |
| 2026-01-27 | Asif Ali | Sell | $83.13 | 46,203 | $3.8M |
| 2026-01-27 | Dinesh V Ph D Patel | Sell | $83.19 | 4,068 | $338,417 |
| 2026-01-26 | Dinesh V Ph D Patel | Sell | $84.03 | 24,890 | $2.1M |
| 2026-01-23 | Arturo Md Molina | Sell | $82.42 | 13,151 | $1.1M |
| 2026-01-23 | Dinesh V Ph D Patel | Sell | $84.59 | 19,315 | $1.6M |
| 2026-01-20 | Arturo Md Molina | Sell | $82.48 | 9,514 | $784,715 |
| 2026-01-20 | Asif Ali | Sell | $82.48 | 8,588 | $708,338 |
| 2026-01-20 | Dinesh V Ph D Patel | Sell | $82.48 | 34,438 | $2.8M |
| 2025-10-10 | William D Waddill | Sell | $81.62 | 12,000 | $979,440 |
| 2025-09-22 | William D Waddill | Sell | $64.25 | 4,000 | $257,000 |
| 2025-08-27 | William D Waddill | Sell | $59.25 | 4,000 | $237,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
PTGX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns PTGX
Institutional investors own 119.7% of Protagonist Therapeutics's shares and insiders 0.71%. The largest holder is BlackRock Inc with 15.93% of the shares (10.3M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 5 reduced their stake in the latest filings. Short interest is 16.78% of the float, or 13.63 days of average trading volume. The share count rose 980.3% since 2015.
Related: PTGX analyst forecast, PTGX key metrics. See the PTGX stock overview for the latest quote and news.
PTGX ownership FAQ
Who owns the most Protagonist Therapeutics stock?
The largest shareholders of Protagonist Therapeutics are BlackRock Inc (15.93%), Farallon Capital Management, L.L.C. (9.81%), RTW INVESTMENTS, LLC (7.82%), Vanguard Portfolio Management, LLC (5.61%), Wellington Management Company LLP (5.28%).
What percentage of Protagonist Therapeutics is owned by institutions?
Institutions hold 119.7% of Protagonist Therapeutics's shares outstanding; insiders hold 0.71%.
Which funds own Protagonist Therapeutics?
The largest fund holders of Protagonist Therapeutics are iShares Core S&P Small-Cap ETF (5.96%), Vanguard MStar Total Stk Mkt Idx Invest (3.17%), iShares Russell 2000 ETF (2.46%), Vanguard Small Cap Index (2.29%), Vanguard Health Care Inv (2.13%).
What is Protagonist Therapeutics's short interest?
9.3M shares of Protagonist Therapeutics were sold short, 16.78% of the float; at the average daily volume it would take 13.63 days to cover.
Are insiders buying or selling Protagonist Therapeutics?
Of the latest 20 reported insider transactions in Protagonist Therapeutics (since August 27, 2025), 0 were purchases and 20 were sales.
How many shares of Protagonist Therapeutics are outstanding?
Protagonist Therapeutics has 64.7M shares outstanding, of which 52.9M are in the public float.